AmBisome: relationship between the pharmacokinetic characteristics acquired by liposomal formulation and safety/efficacy

References

• Adler-Moore J, Proffitt RT. (2002). AmBisome: liposomal formulation, structure, mechanism of action and pre-clinical experience. J Antimicrob Chemother 49:21–30
   PubMed Web of Science ®Google Scholar
• Adler-Moore JP, Proffitt RT. (1993). Development, characterization, efficacy and mode of action of AmBisome, a unilamellar liposomal formulation of amphotericin B. J Liposome Res 3:429–50
   Google Scholar
• Andes D, Stamsted T, Conklin R. (2001). Pharmacodynamics of amphotericin B in a neutropenic-mouse disseminated-candidiasis model. Antimicrob Agents Chemother 45:922–6
   PubMed Web of Science ®Google Scholar
• Aoun M. (2000). Standard antifungal therapy in neutropenic patients. Int J Antimicrob Agents 16:143–5
   PubMed Web of Science ®Google Scholar
• Bakker-Woudenberg IA, Lokerse AF. (1990). Liposomes and lipid carriers in the treatment of microbial infections. Scand J Infect Dis Suppl 74:34–41
   PubMedGoogle Scholar
• Bekersky I, Fielding RM, Dressler DE, et al. (2002). Plasma protein binding of amphotericin B and pharmacokinetics of bound versus unbound amphotericin B after administration of intravenous liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate. Antimicrob Agents Chemother 46:834–40
   PubMed Web of Science ®Google Scholar
• Clemons KV, Stevens DA. (1993a). Comparison of a liposomal amphotericin B formulation (AmBisome) and deoxycholate amphotericin B (Fungizone) for the treatment of murine paracoccidioidomycosis. J Med Vet Mycol 31:387–94
   Google Scholar
• Clemons KV, Stevens DA. (1993b). Therapeutic efficacy of a liposomal formulation of amphotericin B (AmBisome) against murine blastomycosis. J Antimicrob Chemother 32:465–72
   PubMed Web of Science ®Google Scholar
• Cornely OA, Maertens J, Bresnik M, et al. (2007). Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis 44:1289–97
   PubMed Web of Science ®Google Scholar
• Davis SA, Vincent BM, Endo MM, et al. (2015). Nontoxic antimicrobials that evade drug resistance. Nat Chem Biol 11:481–7
   PubMed Web of Science ®Google Scholar
• Dupont B. (2002). Overview of the lipid formulations of amphotericin B. J Antimicrob Chemother 49:31–6
   PubMed Web of Science ®Google Scholar
• Durbin PW, Jeung N, Kullgren B, Clemons GK. (1992). Gross composition and plasma and extracellular water volumes of tissues of a reference mouse. Health Phys 63:427–42
   PubMed Web of Science ®Google Scholar
• Emmen F, Storm G. (1987). Liposomes in treatment of infectious diseases. Pharm Weekbl Sci 9:162–71
   PubMedGoogle Scholar
• Falk R, Domb AJ, Polacheck I. (1999). A novel injectable water-soluble amphotericin B-arabinogalactan conjugate. Antimicrob Agents Chemother 43:1975–81
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. (1998). AmBisome approval package [Online]. Washington, DC: Center for Drug Evaluation and Research, Food and Drug Administration. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/050740a_081797-6.pdf [last accessed 5 Jul 2016]
   Google Scholar
• Ghannoum MA, Rice LB. (1999). Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clin Microbiol Rev 12:501–17
   PubMed Web of Science ®Google Scholar
• Gonzalez GM, Tijerina R, Najvar LK, et al. (2004). Efficacies of amphotericin B (AMB) lipid complex, AMB colloidal dispersion, liposomal AMB, and conventional AMB in treatment of murine coccidioidomycosis. Antimicrob Agents Chemother 48:2140–3
   PubMed Web of Science ®Google Scholar
• Graybill JR, Craven PC, Taylor RL, et al. (1982). Treatment of murine cryptococcosis with liposome-associated amphotericin B. J Infect Dis 145:748–52
   PubMed Web of Science ®Google Scholar
• Harbarth S, Pestotnik SL, Lloyd JF, et al. (2001). The epidemiology of nephrotoxicity associated with conventional amphotericin B therapy. Am J Med 111:528–34
   PubMed Web of Science ®Google Scholar
• Heinemann V, Bosse D, Jehn U, et al. (1997). Pharmacokinetics of liposomal amphotericin B (Ambisome) in critically ill patients. Antimicrob Agents Chemother 41:1275–80
   PubMed Web of Science ®Google Scholar
• Herbrecht R, Denning DW, Patterson TF, et al. (2002). Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 347:408–15
   PubMed Web of Science ®Google Scholar
• Hong Y, Shaw PJ, Nath CE, et al. (2006). Population pharmacokinetics of liposomal amphotericin B in pediatric patients with malignant diseases. Antimicrob Agents Chemother 50:935–42
   PubMed Web of Science ®Google Scholar
• Janknegt R, de Marie S, Bakker-Woudenberg IA, Crommelin DJ. (1992). Liposomal and lipid formulations of amphotericin B. Clinical pharmacokinetics. Clin Pharmacokinet 23:279–91
   PubMed Web of Science ®Google Scholar
• Janoff AS, Boni LT, Popescu MC, et al. (1988). Unusual lipid structures selectively reduce the toxicity of amphotericin B. Proc Natl Acad Sci USA 85:6122–6
   PubMed Web of Science ®Google Scholar
• Johnson PC, Wheat LJ, Cloud GA, et al. (2002). Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS. Ann Intern Med 137:105–9
   PubMed Web of Science ®Google Scholar
• Kashimoto S, Takemoto K, Yamamoto Y, Kanazawa K. (2010). In vivo activity of liposomal amphotericin B against Exophiala dermatitidis in a murine lethal infection model. Jpn J Antibiot 63:265–72
   PubMedGoogle Scholar
• Kohno S, Kobayashi H, Masaoka T, et al. (2013). Evaluation of efficacy and safety of liposomal amphotericin B (L-AMB) in deep-seated fungal infection. Jpn J Chemother 61:347–68
   Google Scholar
• Koldin MH, Kobayashi GS, Brajtburg J, Medoff G. (1985). Effects of elevation of serum cholesterol and administration of amphotericin B complexed to lipoproteins on amphotericin B-induced toxicity in rabbits. Antimicrob Agents Chemother 28:144–5
   PubMed Web of Science ®Google Scholar
• Kubicová L, Pravda M, Buchta V, et al. (2004). Amphotericin B, its lipid formulations and conjugates with polymers. Cent Eur J Public Health 12:S54–6
   PubMedGoogle Scholar
• Kuse ER, Chetchotisakd P, da Cunha CA, et al. (2007). Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 369:1519–27
   PubMed Web of Science ®Google Scholar
• Lee JW, Amantea MA, Francis PA, et al. (1994). Pharmacokinetics and safety of a unilamellar liposomal formulation of amphotericin B (AmBisome) in rabbits. Antimicrob Agents Chemother 38:713–18
   PubMed Web of Science ®Google Scholar
• Leenders AC, Daenen S, Jansen RL, et al. (1998). Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections. Br J Haematol 103:205–12
   PubMed Web of Science ®Google Scholar
• Lopez-Berestein G, Mehta R, Hopfer RL, et al. (1983). Treatment and prophylaxis of disseminated infection due to Candida albicans in mice with liposome-encapsulated amphotericin B. J Infect Dis 147:939–45
   PubMed Web of Science ®Google Scholar
• Massa T, Sinha DP, Frantz JD, et al. (1985). Subchronic toxicity studies of N-D-ornithyl amphotericin B methyl ester in dogs and rats. Fundam Appl Toxicol 5:737–53
   PubMedGoogle Scholar
• Matsui S, Imai S, Yabuki M, Komuro S. (2009). Pharmacokinetics characterization of liposomal amphotericin B: investigation of clearance process and drug interaction potential. Arzneimittelforschung 59:461–70
   PubMed Web of Science ®Google Scholar
• Mikamo H, Hamada Y, Yamagishi Y. (2013). Pharmacokinetics-pharmacodynamics (PK-PD) of liposomal amphotericin B (L-AMB) in patients with candidemia complicated with diabetes mellitus. 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy; Denver, CO, 10 September, poster M-233
   Google Scholar
• Mikamo H, Yamagishi Y. (2011). Pharmacokinetics-pharmacodynamics (PK-PD) of liposomal amphotericin B (L-AMB) efficacy in non-neutropenic patients with candidemia. 51st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 18 September, poster A2-581
   Google Scholar
• Ostrosky-Zeichner L, Marr KA, Rex JH, Cohen SH. (2003). Amphotericin B: time for a new “gold standard”. Clin Infect Dis 37:415–25
   PubMed Web of Science ®Google Scholar
• Pharmaceuticals and Medical Devices Agency. (2015). Interview form of AmBisome. (In Japanese) [Online]. Tokyo, Japan: Pharmaceuticals and Medical Devices Agency. Available from: http://www.info.pmda.go.jp/go/interview/1/400093_6173400D2023_1_009_1F [last accessed 5 Jul 2016]
   Google Scholar
• Readio JD, Bittman R. (1982). Equilibrium binding of amphotericin B and its methyl ester and borate complex to sterols. Biochim Biophys Acta 685:219–24
   PubMed Web of Science ®Google Scholar
• Reuhl KR, Vapiwala M, Ryzlak MT, Schaffner CP. (1993). Comparative neurotoxicities of amphotericin B and its mono-methyl ester derivative in rats. Antimicrob Agents Chemother 37:419–28
   PubMed Web of Science ®Google Scholar
• Ryan KA. (1996). Amphotericin B infused in 20% lipid emulsion. J Intraven Nurs 19:123–5
   PubMedGoogle Scholar
• Sabra R, Branch RA. (1990). Amphotericin B nephrotoxicity. Drug Saf 5:94–108
   PubMed Web of Science ®Google Scholar
• Saint-Julien L, Joly V, Seman M, et al. (1992). Activity of MS-8209, a nonester amphotericin B derivative, in treatment of experimental systemic mycoses. Antimicrob Agents Chemother 36:2722–8
   PubMed Web of Science ®Google Scholar
• Salmaso S, Caliceti P. (2013). Stealth properties to improve therapeutic efficacy of drug nanocarriers. J Drug Deliv 2013:374252
   PubMedGoogle Scholar
• Shimizu K, Osada M, Takemoto K, et al. (2010). Temperature-dependent transfer of amphotericin B from liposomal membrane of AmBisome to fungal cell membrane. J Control Release 141:208–15
   PubMed Web of Science ®Google Scholar
• Takemoto K, Yamamoto Y, Kanazawa K. (2010). Comparative study of the efficacy of liposomal amphotericin B and amphotericin B deoxycholate against six species of Zygomycetes in a murine lethal infection model. J Infect Chemother 16:388–95
   PubMed Web of Science ®Google Scholar
• Takemoto K, Yamamoto Y, Ueda Y, et al. (2004). Comparative studies on the efficacy of AmBisome and Fungizone in a mouse model of disseminated aspergillosis. J Antimicrob Chemother 53:311–17
   PubMed Web of Science ®Google Scholar
• Takemoto K, Yamamoto Y, Ueda Y. (2006a). Evaluation of antifungal pharmacodynamic characteristics of AmBisome against Candida albicans. Microbiol Immunol 50:579–86
   PubMed Web of Science ®Google Scholar
• Takemoto K, Yamamoto Y, Ueda Y. (2006b). Influence of the progression of cryptococcal meningitis on brain penetration and efficacy of AmBisome in a murine model. Chemotherapy 52:271–8
   PubMed Web of Science ®Google Scholar
• Takemoto K, Yamamoto Y, Ueda Y, et al. (2006c). Comparative study on the efficacy of AmBisome and Fungizone in a mouse model of pulmonary aspergillosis. J Antimicrob Chemother 57:724–31
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Finberg RW, Arndt C, et al. (1999). Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 340:764–71
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Yeldandi V, McEvoy M, et al. (1998). Safety, tolerance, and pharmacokinetics of a small unilamellar liposomal formulation of amphotericin B (AmBisome) in neutropenic patients. Antimicrob Agents Chemother 42:2391–8
   PubMed Web of Science ®Google Scholar
• Watanabe A, Matsumoto K, Igari H, et al. (2010). Comparison between concentrations of amphotericin B in infected lung lesion and in uninfected lung tissue in a patient treated with liposomal amphotericin B (AmBisome). Int J Infect Dis 14:e220–3
   PubMed Web of Science ®Google Scholar
• Xu P, Tan G, Zhou J, et al. (2009). Undulating tubular liposomes through incorporation of a synthetic skin ceramide into phospholipid bilayers. Langmuir 25:10422–5
   PubMed Web of Science ®Google Scholar